ClinicalTrials.gg
CompletedNCT00299325VICTORIAUpdated Jun 6, 2016

VIsceral Fat Reduction Assessed by CT-scan On RImonabAnt

A Phase 3 interventional study of Rimonabant and Placebo (for Rimonabant) in Metabolic Syndrome, sponsored by Sanofi. Completed at 9 sites in 9 countries. Open to participants aged 35 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-06-06.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
254
Allocation
Randomized
Ages
35 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 579 studies in Metabolic Syndrome with a site in United States — 62 open to participants now, 84 under way, 3 of them phase 3. Metabolic Syndrome · United States.

Enrollment
42nd of 491
254 · median 48
Started
2006
with 39 others
Phase 3
12 of 579
none open now
Registered
50th of 579
by date

Among the 579 studies in Metabolic Syndrome with a site in United States, this one is the 42nd largest by enrollment of the 491 interventional ones that give a count, is one of 40 that started in 2006, is one of 12 in phase 3, and was the 50th registered.

Metabolic Syndrome

2,117 studies on the registry are indexed under Metabolic Syndrome; 347 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

62 of the 579 studies in Metabolic Syndrome with a site in United States are open now. Recruiting first, the newest first:

57 more — sign in →

All 62 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 232 Metabolic Syndrome studies recruiting now, 68 (29%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 80 take healthy volunteers.

This study: 35 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 579 studies in Metabolic Syndrome with a site in United States, or all of them as a file.
02

Study summary

Primary objective:

To assess the effect of rimonabant on visceral fat area over a period of 12 months when prescribed with a mild hypocaloric diet in abdominally obese patients with metabolic syndrome

Secondary objectives:

  • To assess the effect of rimonabant over a period of 12 months on:

    • Liver fat content using CT scan (Computed Tomography scan)
    • Anthropometric measures (weight, waist circumference, body composition using Dual Energy X-ray Absorptiometry (DEXA))
    • Lipid, lipoprotein profile
    • Glycemia, insulinemia and HbA1c
    • Adipokines, inflammatory and hemostatic markers
  • To evaluate the percentage of patients with metabolic syndrome at 12 months
  • To evaluate the safety and tolerability of rimonabant in these patients

In four selected US sites the effect of rimonabant at 12 months will be also assessed on:

  • Basal lipolysis and insulin suppressed lipolysis (euglycemic hyperinsulinemic clamp).
  • Resting metabolic rate and substrate oxidation at rest using indirect calorimetry.
  • Adipose tissue histology and expression of genes involved in glucose and lipid metabolism (superficial adipose tissue biopsy).
Read the detailed description

The total duration per patient will be approximately 15 months including a 12-month double-blind treatment period.

03

Conditions studied

  • Metabolic Syndrome

Browse trials for

04

Who can participate

Ages eligible
35 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Waist circumference > 102 cm in men and > 88 cm in women
  • Two other components of the metabolic syndrome (NCEP/ATPIII definition) among the following :

    • Triglyceridemia ≥ 150 mg/dl (or 1.69 mmol/L)
    • HDL cholesterol \< 50 mg/dL (or 1.29 mmol/L) in women or \< 40 mg/dL (or 1.04 mmol/L) in men
    • Blood pressure ≥ 130/85 mmHg (systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 85 mmHg) or Treatment with antihypertensive agent(s) for this condition
    • Fasting blood glucose > 110 mg/dl (or 6.1 mmol/L)

Exclusion criteria

Exclusion criteria :

  • Positive pregnancy test, pregnant or breast-feeding women, or women planning to become pregnant or breastfeed
  • Absence of medically approved methods for female of
  • History of very low-calorie diet (≤ 800 kcal/day) within 3 months prior to screening visit
  • History of surgical procedures for weight loss (eg, stomach stapling, bypass).
  • Presence of any endocrine disease according to the investigator.
  • Weight change > 5 kg within 3 months prior to screening visit
  • Obese patients (> 40 kg/m²)
  • Established type 1 or 2 diabetes (treated or untreated): at least 2 measures of fasting blood glucose ≥ 126 mg/dl
  • Severe renal dysfunction ( \< 30 ml/min) or nephrotic syndrome
  • Chronic hepatitis or clinically significant hepatic disease
  • Positive test for or C
  • Marijuana or hashish users
  • Significant haematology abnormalities ( \< 100 g/L and/or neutrophils \< 1.5 G/L and/or \< 100 G/L).
  • Presence or history of cancer within the past 5 years with the exception of adequately treated basal cell skin cancer or in situ uterine cervical cancer
  • Presence or history of severe depression that can be defined as depression which necessitated the patient to be hospitalised, or patient with 2 or more recurrent episodes of depression or an history of suicide attempt
  • Presence or history of bulimia or anorexia nervosa ( (Diagnostic and Statistical Manual of Mental Disorders) criteria) or binge eating disorders
  • Presence of any other condition (eg geographical, social...) current or anticipated that the Investigator feels that would restrict or limit the subject's participation for the duration of the studyRelated to previous or concomitant drugs that could interfere with the evaluation of study drug effects
  • Administration of any treatment (drug or device) within 30 days prior to screening
  • Previous participation in a rimonabant study
  • Administration of any of the following within 3 months prior to screening visit:

    • anti obesity drugs (eg, sibutramine, orlistat)
    • other drugs for weight reduction (phentermine, amphetamines)
    • herbal preparations for weight reduction
    • thyroid preparations or thyroxin treatment (except in patients on replacement therapy on a stable dose)
  • Patient treated within the last 3 months with nicotinic acid, fibrates, bile acid sequestrants or ezetimibe (patients treated with statins can be included if the dose received is stable since at least 3 months and should not be modified during the whole study period).
  • Patient treated with antidiabetic drug(s).
  • Prolonged use (more than one week) within the last 3 months of systemic , neuroleptics, or antidepressants (including bupropion).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
254 participants (actual)

Study arms

  • Experimental
    Rimonabant

    Rimonabant 20 mg once daily with mild hypocaloric diet

    Drug: Rimonabant · Other: Mild hypocaloric diet

  • Placebo comparator
    Placebo

    Placebo (for Rimonabant) once daily with mild hypocaloric diet

    Drug: Placebo (for Rimonabant) · Other: Mild hypocaloric diet

Interventions

  • Tablet, oral administration

    Also known as: SR141716, Acomplia

  • DrugPlacebo (for Rimonabant)

    Tablet, oral administration

  • OtherMild hypocaloric diet

    Calculated by the dietitian based on the estimated basal metabolism rate and the physical activity

06

What researchers measure

Primary outcomes

  1. Relative change in visceral fat area assessed by CT scan

    Time frame: From baseline to Month 12

Secondary outcomes

  1. Absolute change in visceral fat area assessed by CT scan

    Time frame: From baseline to Month 12

  2. Change in Liver fat content measured using CT scan

    Time frame: From baseline to Month 12

  3. Change in anthropometric measures

    Time frame: From baseline to Month 12

  4. Change in specific lipid parameters

    Time frame: From baseline to Month 12

  5. Change in glucose control parameters

    Time frame: From baseline to Month 12

  6. Change in adipokines, inflammatory and hemostatic markers

    Time frame: From baseline to Month 12

  7. Percentages of patients with a metabolic syndrome

    Time frame: At 12 months

07

Study locations

9 sites
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
  • Sanofi-Aventis Administrative Office
    Laval, Canada
  • Sanofi-Aventis Administrative Office
    Hoersholm, Denmark
  • Sanofi-Aventis Administrative Office
    Helsinki, Finland
  • Sanofi-Aventis Administrative Office
    Paris, France
  • Sanofi-Aventis Administrative Office
    Milan, Italy
  • Sanofi-Aventis Administrative Office
    Barcelona, Spain
  • Sanofi-Aventis Administrative Office
    Stockholm, Sweden
  • Sanofi-Aventis Administrative Office
    Guildford, United Kingdom
08

References and documents

Publications

  • Triay J, Mundi M, Klein S, Toledo FG, Smith SR, Abu-Lebdeh H, Jensen M. Does rimonabant independently affect free fatty acid and glucose metabolism? J Clin Endocrinol Metab. 2012 Mar;97(3):819-27. doi: 10.1210/jc.2011-2486. Epub 2011 Dec 14. PubMed 22170727 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2006
First posted
Mar 6, 2006
Start
Feb 2006
Primary completionActual
Jul 2008
CompletionActual
Jul 2008
Results delay requested
Apr 21, 2016
Last update
Jun 6, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00299325
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 6, 2006
Start date
Feb 2006
Primary completion
Jul 2008
Completion
Jul 2008
Last update
Jun 6, 2016

Study contacts

Valérie Pilorget, MD
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimonabant

Start the discussion